Spiraprilat

Last updated
Spiraprilat
Spiraprilat.svg
Identifiers
  • (8S)-7-[(2S)-2-{[(1S)-1-Carboxy-3-phenylpropyl]amino}propanoyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C20H26N2O5S2
Molar mass 438.56 g·mol−1
3D model (JSmol)
  • C[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N2CC3(C[C@H]2C(=O)O)SCCS3
  • InChI=1S/C20H26N2O5S2/c1-13(21-15(18(24)25)8-7-14-5-3-2-4-6-14)17(23)22-12-20(28-9-10-29-20)11-16(22)19(26)27/h2-6,13,15-16,21H,7-12H2,1H3,(H,24,25)(H,26,27)/t13-,15-,16-/m0/s1
  • Key:FMMDBLMCSDRUPA-BPUTZDHNSA-N

Spiraprilat is the active metabolite of spirapril. [1]

Related Research Articles

ATC code C09Agents acting on the renin–angiotensin system is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. Subgroup C09 is part of the anatomical group C Cardiovascular system.

References

  1. Noble S, Sorkin EM (May 1995). "Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension". Drugs. 49 (5): 750–66. doi:10.2165/00003495-199549050-00008. PMID   7601014. S2CID   195691037.